Gain Therapeutics – a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies – announced that Gene Mack, who has served as the company’s Chief Financial Officer since April 2024 and interim CEO since June 2024, has been appointed President and Chief Executive Officer. Mack has also been appointed as a member of the company’s Board of Directors.
Gianluca Fuggetta, the company’s current Finance Vice President, has also been appointed Senior Vice President of Finance and the Company’s Principal Financial Officer.
Gene has over 25 years of experience in the life sciences sector, spanning clinical research, financing and capital markets, investing, corporate strategy, and business development. Before joining Gain, Gene was CFO at privately held Imcyse SA between 2021 and 2023. Before Imcyse, Gene was CFO at OncoC4, a privately held biotechnology company that spun out of Merck & Co’s (MSD) acquisition of OncoImmune in 2020, where he had also been CFO. Before that, he was CFO for several development- and commercial-stage biopharmaceutical companies. Before his operational experience, Gene covered the biotechnology and life sciences sector as a senior publishing analyst at various investment banks, including Gruntal & Co, Lazard, Mizuho, and HSBC. Gene received his BS in Biochemistry and MBA in Finance from Fordham University.
KEY QUOTES:
“On behalf of the Board of Directors, I am pleased to announce that Mr. Gene Mack has been promoted to lead Gain Therapeutics as Chief Executive Officer. Over the last nine months Gene has served as both our CFO and interim CEO and has demonstrated a leadership approach that supports strong alignment between the Company’s short-term and long-term objectives. Gene’s appointment as CEO will maintain continuity as GT-02287 advances through clinical development. Since joining Gain, Gene has proven himself to be a strategic and effective leader who is focused on achieving the Company’s goals for patients, shareholders, and other stakeholders. It is also my pleasure to welcome Gene to the Board of Directors and I look forward to his contributions in the future. Following Gene’s appointment as CEO, I will no longer maintain an executive role in the Company but will continue in my function as Chairman of the Board of Directors.”
– Dr. Islam, Chairman of the Board of Directors
“I am honored by the opportunity to lead the passionate team we have here at Gain – a team that I have grown very fond of after experiencing firsthand during 2024 how uniformly committed everyone is to our mission of developing truly disease-altering treatments that go beyond temporary symptom relief. I look forward to providing continuing support and contributing to the impressive work being done by my colleagues at Gain as we guide our lead candidate, GT-02287, through the currently ongoing Phase 1b trial in people with Parkinson’s Disease during the first half of 2025, while also preparing for potential Phase 2 activities during the second half of 2025.”
– Gene Mack, newly appointed CEO of Gain
